You are here
Chimeric antigen receptor T cell therapy (CAR-T cell): guidelines for costing, counting and reconciliation of funding18 June 2020
The guidelines set out the scope, funding, costing, counting and reconciliation of funding for the chimeric antigen receptor T cell therapy (CAR-T cell) immunotherapy program using the Novartis CAR-T product Kymriah. The CAR-T program is for paediatric and young adults (up to 25 years) with Acute Lymphoblastic Leukaemia (ALL) who relapse or do not respond to initial therapy.
This guide is intended to provide assistance when assigning care types, especially for those patients that may potentially have care that applies to more than one care type.
IHPA has developed a robust set of standard costs for the revised List of standard items associated with conducting clinical trials in Australia.
*The documents on this page may not meet accessibility (WCAG 2.0) requirements. If you need help please contact us using the enquiries.ihpa [at] ihpa.gov.au (IHPA enquiries).